Abstract

) With the Support of the NCDDG, the Experimental Therapeutics Group at MSKCC developed a core expertise in the evaluation of telomerase activity and telomere measurements in clinical samples from patients with a variety of malignancies. In addition, in vivo a number of different leukemia and solid xenograft tumor models were established for evaluating telomerase inhibitor candidates from collaborators in the Screening and Medicinal Chemistry Groups at Geron. The role of Experimental Therapeutics Group is to develop and evaluate lead telomerase candidates in in viva tumor models. As lead candidates are developed that overcome hurdles of potency and selectivity, they will progress to cell-based assays. Depending on the efficacy of lead compounds in a spectrum of human tumor cell lines, the telomerase inhibitor will be evaluated in an appropriate in viva model

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA067842-08
Application #
6646617
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
Geron Corporation
Department
Type
DUNS #
City
Menlo Park
State
CA
Country
United States
Zip Code
94025

  Publications

Gammaitoni, Loretta; Weisel, Katja C; Gunetti, Monica et al. (2004) Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood 103:4440-8
Wang, Eunice S; Wu, Kaida; Chin, Allison C et al. (2004) Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103:258-66
Asai, Akira; Oshima, Yuko; Yamamoto, Yoshihiro et al. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63:3931-9
Franco, S; Ozkaynak, M F; Sandoval, C et al. (2003) Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia 17:401-10
Wu, Kai-Da; Orme, Lisa M; Shaughnessy Jr, John et al. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101:4982-9
Boklan, Jessica; Nanjangud, Gouri; MacKenzie, Karen L et al. (2002) Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer Res 62:2104-14
Franco, S; MacKenzie, K L; Dias, S et al. (2001) Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Res 268:14-25
Engelhardt, M; Mackenzie, K; Drullinsky, P et al. (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 60:610-7
Albanell, J; Bosl, G J; Reuter, V E et al. (1999) Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst 91:1321-6
Engelhardt, M; Ozkaynak, M F; Drullinsky, P et al. (1998) Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12:13-24

Showing the most recent 10 out of 17 publications